BRAF V600E/K OR NRAS mutation — drives BRAFi+MEKi vs ICI doublet decision.

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

ID	`RF-MELANOMA-HIGH-RISK-BIOLOGY`
Type	Red flag
Status	pending_clinical_signoff
Diseases	`DIS-MELANOMA`
Sources	`SRC-ESMO-MELANOMA-2024` `SRC-NCCN-MELANOMA-2025`

Red Flag Origin

Definition	BRAF V600E/K OR NRAS mutation — drives BRAFi+MEKi vs ICI doublet decision.
Clinical direction	intensify
Category	high-risk-biology

Trigger Logic

{
  "any_of": [
    {
      "finding": "BIO-BRAF-V600E",
      "value": "positive"
    },
    {
      "finding": "nras_mutation",
      "value": true
    }
  ],
  "type": "biomarker"
}

Notes

BRAF testing universal in metastatic. DREAMseq established ICI-first sequencing.

Used By

No reverse references found in the YAML corpus.